A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes

被引：0

作者：

Kosei Kimura

Mitsuhiko Iwamoto

Satoru Tanaka

Daigo Yamamoto

Katsuhide Yoshidome

Hiroyuki Ogura

Risa Terasawa

Nobuki Matsunami

Yuko Takahashi

Toshikatsu Nitta

Takashi Morimoto

Hiroya Fujioka

Kanako Kawaguchi

Kazuhisa Uchiyama

机构：

[1] Osaka Medical College Hospital,Department of Breast and Endocrine Surgery

[2] National Hospital Organization Osaka Minami Medical Center,Department of Breast Surgery

[3] Kansai Medical University Medical Center,Department of Breast Surgery

[4] Osaka Police Hospital,Department of Breast and Endocrine Surgery

[5] Hamamatsu University School of Medicine,Department of Breast Surgery

[6] Osaka Rosai Hospital,Department of Breast Surgery

[7] Hirakata City Hospital,Department of Breast and Endocrine Surgery

[8] Medico Shunju Shiroyama Hospital Breast Center,Division of Surgery

[9] Yao Municipal Hospital,Department of Breast Surgery

来源：

Cancer Chemotherapy and Pharmacology | 2018年 / 81卷

关键词：

Eribulin; Metastatic breast cancer; First or second-line; Objective response rate; QOL;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：923 / 933

页数：10

共 50 条

[11] Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study
Shogo Nakamoto
Junichiro Watanabe
Shoichiro Ohtani
Satoshi Morita
Masahiko Ikeda
BMC Cancer, 22
[12] Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study
Nakamoto, Shogo
Watanabe, Junichiro
Ohtani, Shoichiro
Morita, Satoshi
Ikeda, Masahiko
BMC CANCER, 2022, 22 (01)
[13] Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial
Perez-Garcia, Jose M.
Llombart-Cussac, Antonio
Cortes, Maria G.
Curigliano, Giuseppe
Lopez-Miranda, Elena
Alonso, Jose L.
Bermejo, Begona
Calvo, Lourdes
Caranana, Vicente
de la Cruz Sanchez, Susana
Vazquez, Raul M.
Prat, Aleix
Borrego, Manuel R.
Sampayo-Cordero, Miguel
Segui-Palmer, Miguel A.
Soberino, Jesus
Malfettone, Andrea
Schmid, Peter
Cortes, Javier
EUROPEAN JOURNAL OF CANCER, 2021, 148 : 382 - 394
[14] A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
Schuler, Martin
Awada, Ahmad
Harter, Philipp
Canon, Jean Luc
Possinger, Kurt
Schmidt, Marcus
De Greve, Jacques
Neven, Patrick
Dirix, Luc
Jonat, Walter
Beckmann, Matthias W.
Schuette, Jochen
Fasching, Peter A.
Gottschalk, Nina
Besse-Hammer, Tatiana
Fleischer, Frank
Wind, Sven
Uttenreuther-Fischer, Martina
Piccart, Martine
Harbeck, Nadia
BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (03) : 1149 - 1159
[15] A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
Martin Schuler
Ahmad Awada
Philipp Harter
Jean Luc Canon
Kurt Possinger
Marcus Schmidt
Jacques De Grève
Patrick Neven
Luc Dirix
Walter Jonat
Matthias W. Beckmann
Jochen Schütte
Peter A. Fasching
Nina Gottschalk
Tatiana Besse-Hammer
Frank Fleischer
Sven Wind
Martina Uttenreuther-Fischer
Martine Piccart
Nadia Harbeck
Breast Cancer Research and Treatment, 2012, 134 : 1149 - 1159
[16] Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) (May, 2021, 10.1007/s10147-021-01920-0)
Aogi, Kenjiro
Watanabe, Kenichi
Kitada, Masahiro
Sangai, Takafumi
Ohtani, Shoichiro
Aruga, Tomoyuki
Kawagichi, Hidetoshi
Fujisawa, Tomomi
Maeda, Shigeto
Morimoto, Takashi
Sato, Nobuaki
Takao, Shintaro
Morita, Satoshi
Masuda, Norikazu
Toi, Masakazu
Ohno, Shinji
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (07) : 1237 - 1237
[17] Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies
O'Shaughnessy, Joyce
McIntyre, Kristi
Schwartzberg, Lee
Wilks, Sharon
Puhalla, Shannon
Berrak, Erhan
Song, James
Vahdat, Linda
SPRINGERPLUS, 2015, 4
[18] Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study
Manso, Luis
Moreno Anton, Fernando
Izarzugaza Peron, Yann
Delgado Mingorance, Juan, I
Borrega Garcia, Pablo
Echarri Gonzalez, Maria J.
Martinez-Janez, Noelia
Lopez-Gonzalez, Ana
Olier Garate, Clara
Ballesteros Garcia, Anabel
Chacon Lopez-Muniz, Ignacio
Ciruelos Gil, Eva
Angel Garcia-Saenz, Jose
Paz-Ares, Luis
BREAST JOURNAL, 2019, 25 (02) : 219 - 225
[19] Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Tamura, Kenji
Inoue, Kenichi
Masuda, Norikazu
Takao, Shintaro
Kashiwaba, Masahiro
Tokuda, Yutaka
Iwata, Hiroji
Yamamoto, Naohito
Aogi, Kenjiro
Saeki, Toshiaki
Nakayama, Takahiro
Sato, Nobuaki
Toyama, Tatsuya
Ishida, Takanori
Arioka, Hitoshi
Saito, Mitsue
Ohno, Shinji
Yamauchi, Hideko
Yamada, Kimito
Watanabe, Junichiro
Ishiguro, Hiroshi
Fujiwara, Yasuhiro
CANCER SCIENCE, 2017, 108 (05): : 987 - 994
[20] Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Xavier Pivot
Seock Ah Im
Matthew Guo
Frederik Marmé
Breast Cancer, 2018, 25 : 370 - 374

← 1 2 3 4 5 →